Amgen (AMGN) Stock Price, News & Analysis

Company Overview

Amgen Inc. (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease. Notable marketed medicines developed or commercialized by the company include epoetin and darbepoetin products for anemia, granulocyte colony-stimulating factor therapies for infection risk reduction, bone-targeting agents for osteoporosis and skeletal complications, and a PCSK9 inhibitor for lipid management. The company also develops and markets biosimilars and newer targeted therapies emerging from its research programs.

Research and development is a core activity at Amgen, combining laboratory science, clinical trials and manufacturing capabilities to advance novel biologics and biosimilars. The company operates large-scale biologics manufacturing facilities and maintains a global commercial presence, selling products in North America, Europe, Asia-Pacific and other markets through its own commercial organization and in partnership with other companies. Strategic collaborations, licensing and selective acquisitions have been part of Amgen’s approach to broaden its pipeline and reach.

Amgen is governed by an executive leadership team and board of directors and emphasizes long-term investment in R&D, manufacturing quality and regulatory compliance. Its public-facing strategy highlights innovation in biologics, efforts to expand access to therapies worldwide, and ongoing development programs across multiple therapeutic areas.

Key Stats

• Today's Range: $338.40 to $343.80
• 50-Day Range: $324.39 to $367.79
• 52-Week Range: $267.83 to $391.29
• Volume: 1.57 million shs
• Average Volume: 2.82 million shs
• Market Capitalization: $183.11 billion
• P/E Ratio: 23.61
• Dividend Yield: 2.97%
• Price Target: $355.19
• Consensus Rating: Hold

Amgen Stock Analysis - MarketRank™

Amgen scored higher than 78% of companies evaluated by MarketBeat, and ranked 149th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Amgen has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 2 strong buy ratings, 13 buy ratings, 14 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Amgen is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amgen has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 5.32%

Earnings Growth

Earnings for Amgen are expected to grow by 5.32% in the coming year, from $22.37 to $23.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amgen is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amgen is 23.61, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.

Price to Earnings Growth Ratio

Amgen has a PEG Ratio of 3.41. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amgen has a P/B Ratio of 19.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.42% of the float of Amgen has been sold short.

Short Interest Ratio / Days to Cover

Amgen has a short interest ratio ("days to cover") of 5.28.

Change versus previous month

Short interest in Amgen has recently increased by 1.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Amgen pays a meaningful dividend of 2.97%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Amgen has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Amgen is 70.15%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Amgen will have a dividend payout ratio of 42.78% next year. This indicates that Amgen will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.09

News Sentiment

Amgen has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 52 news articles for Amgen this week, compared to 13 articles on an average week.

Search Interest

41 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.

MarketBeat Follows

29 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 263% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $400,454.00 in company stock.

Percentage Held by Insiders

0.85% of the stock of Amgen is held by insiders.

Percentage Held by Institutions

76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/6 Dividend: 2/13/2026
• Ex-Dividend for 3/6 Dividend: 2/13/2026
• Dividend Payable: 3/06/2026
• Last Earnings: 4/30/2026
• Record date for 6/5 Dividend: 5/15/2026
• Ex-Dividend for 6/5 Dividend: 5/15/2026
• Today: 5/24/2026
• Dividend Payable: 6/05/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AMGN
• CIK: 318154
• Web: www.amgen.com
• Phone: (805) 447-1000
• Fax: 805-447-1010
• Employees: 31,500
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Amgen: $355.19
• High Price Target: $427.00
• Low Price Target: $200.00
• Potential Upside/Downside: +4.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.48
• Research Coverage: 31 Analysts

Profitability

• EPS (Trailing Twelve Months): $14.37
• Trailing P/E Ratio: 23.61
• Forward P/E Ratio: 15.17
• P/E Growth: 3.41
• Net Income: $7.71 billion
• Net Margins: 20.96%
• Pretax Margin: 24.41%
• Return on Equity: 137.41%
• Return on Assets: 13.28%

Debt

• Debt-to-Equity Ratio: 5.65
• Current Ratio: 1.26
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: $36.75 billion
• Price / Sales: 4.98
• Cash Flow: $33.79 per share
• Price / Cash Flow: 10.04
• Book Value: $17.03 per share
• Price / Book: 19.92

Miscellaneous

• Outstanding Shares: 539,680,000
• Free Float: 535,098,000
• Market Cap: $183.11 billion
• Optionable: Optionable
• Beta: 0.44